Deborah Glasser: Nasdaq Bell Celebrating FDA Approval of Novel ITP Therapy
Deborah Glasser, Head of Specialty Care for Sanofi, shared a post on LinkedIn:
”Yesterday, I had the opportunity to ring the Nasdaq closing bell, surrounded by Sanofi colleagues and representatives from the Platelet Disorder Support Association – PDSA. I’m so grateful that PDSA joined us on this special occasion to celebrate ITP Awareness Month, and to recognize the recent FDA approval of a novel treatment. By targeting root causes through multi-immune modulation, this new medicine represents a significant step forward for patients living with immune thrombocytopenia (ITP), a complex immune dysregulation disease, which can cause symptoms that disrupt daily life.
This moment reflects the power of science, collaboration, and our shared commitment to improving patient outcomes. At Sanofi, we continue to push the boundaries of immunoscience to make a meaningful difference for individuals affected by rare conditions like ITP.”
Stay updated with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera